title: Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.
authors.affiliation: HELIOS - Klinikum Erfurt, 2. Medizinische Klinik, Department of Hematology/Oncology, Nordhäuserstrasse 74, Germany. miherold@erfurt.helios-kliniken.de
authors.forename: M
authors.initials: M
authors.lastname: Herold
authors.forename: G
authors.initials: G
authors.lastname: Dölken
authors.forename: F
authors.initials: F
authors.lastname: Fiedler
authors.forename: A
authors.initials: A
authors.lastname: Franke
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: W
authors.initials: W
authors.lastname: Helbig
authors.forename: R
authors.initials: R
authors.lastname: Pasold
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000633:toxicity; D002699:Chlorambucil / Q000008:administration & dosage; D002985:Clinical Protocols; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D018579:Patient Selection; D011239:Prednisolone / Q000008:administration & dosage; D011446:Prospective Studies; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D002699:Chlorambucil; D000069283:Rituximab; D011239:Prednisolone; D008942:Mitoxantrone